The Trump administration will not proceed with a Biden-era proposal to cover anti-obesity drugs under Medicare and Medicaid. The decision comes in light of high costs associated with the proposed coverage, which could have allowed drugs like Wegovy and Zepbound to be accessible to 7 million Americans. Current law restricts Medicare from covering drugs used solely for weight loss, leading to a continuation of existing policies. Secretary Robert F. Kennedy Jr. has previously expressed skepticism towards these medications, advocating for lifestyle changes instead.